{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"VOCGZWPYRQJUMY-UHFFFAOYSA-N","prefName":"CUMYL-CB-MEGACLONE","symbol":"CUMYL-CB-MEGACLONE","iupacName":"5-(cyclobutylmethyl)-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one","aliases":["CUMYL-CBMEGACLONE","CUMYL-CBMGACLONE","SGT273","U43QX7LH63","Cumyl-cyclobutyl-megaclone"],"cas":null,"pubchemCid":"155884737","chebiId":null,"smiles":"CC(C)(C1=CC=CC=C1)N2C=CC3=C(C2=O)C4=CC=CC=C4N3CC5CCC5","molecularFormula":"C25H26N2O","molecularWeight":370.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/155884737"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No known biosynthetic pathway: a fully synthetic molecule, obtained by clandestine chemical synthesis on a gamma-carbolinone core. Only the class of synthesis is described here.","originNote":"A fully synthetic molecule, from the clandestine synthesis of SCRAs (Giorgetti et al., 2025). It belongs to the wave of cyclobutylmethyl SCRAs that appeared around 2019-2020. Pulver et al. (2023) state that this side chain made it possible to bypass the German legislation in force at the time.","discovered":""},"pharmacology":{"summaryFr":"CUMYL-CB-MEGACLONE is a full agonist of the CB1 receptor and the cyclobutylmethyl analogue of CUMYL-PEGACLONE, built on a gamma-carbolinone core. Pulver et al. (2023) report, for their series of three cyclobutylmethyl SCRAs, Ki values of 0.65 to 29.4 nM and EC50 values of 40.1 to 483 nM, with no isolated constant for this compound in the abstract; Giorgetti et al. (2025) state that it has higher affinity and potency than CUMYL-CBMICA and CUMYL-CBMINACA. The parent molecule was not found in authentic urine, which yielded 15 phase I metabolites: a monohydroxylation of the cyclobutylmethyl chain serves as a marker. No human pharmacokinetic, clinical or toxicological study was identified in the sources consulted. In France, it is not named on the list of narcotics of February 2026 and may fall under a generic clause; internationally, it does not appear in the INCB Green List 2026.","receptorSummaryFr":"A full agonist of the CB1 receptor according to Pulver et al. (2023), who compared six SCRAs. For the series of three cyclobutylmethyl SCRAs, this work reports Ki values of 0.65 to 29.4 nM and EC50 values of 40.1 to 483 nM; the abstract gives no isolated constant for CUMYL-CB-MEGACLONE. Giorgetti et al. (2025) state that this compound shows higher affinity and potency than CUMYL-CBMICA and CUMYL-CBMINACA. No published CB2 constant was found in the sources consulted, nor any data on other targets.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":76,"reported":"Ki de 0,65 à 29,4 nM et EC50 de 40,1 à 483 nM pour la série des trois SCRA à chaîne cyclobutylméthyle (Pulver et coll., 2023) ; constante propre à CUMYL-CB-MEGACLONE non isolée dans le résumé consulté","confidence":"medium"}],"references":[{"label":"Pulver et coll., pharmacologie et prévalence en Allemagne des SCRA à chaîne cyclobutylméthyle et norbornylméthyle, Drug Test Anal, 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"Giorgetti et coll., métabolisme de phase I humain du Cumyl-CBMEGACLONE et de deux analogues, Drug Test Anal, 2025","pmid":"39218806","doi":"10.1002/dta.3791","url":"https://pubmed.ncbi.nlm.nih.gov/39218806/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexes III et IV)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (listes de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-CB-MEGACLONE, CID 155884737","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/155884737"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":12},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":5},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":12},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":20},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":18}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"evolving","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised control measure at European Union level is documented in the sources consulted: control therefore falls under national legislation. In Germany, the NpSG law was extended in 2019 to the gamma-carbolinone core, then amended in 2020 to place all cyclobutylmethyl SCRAs under control (Giorgetti et al., 2025; Pulver et al., 2023).","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Not named in the consolidated list of narcotics updated on 16 February 2026 by ANSM, which does however name several gamma-carbolinones: Cumyl-pegaclone (decision of 30 August 2022), 5F-Cumyl-pegaclone and CUMYL-CH-MEGACLONE (decision of 22 May 2024). It could fall under the generic definition of 3-carboxamide indole derivatives (annex IV). On a literal reading, its indole bears a cycloalkylmethyl group on the nitrogen, and the nitrogen of the carboxamide bridge carries a cumyl group while belonging to a ring. The attachment nonetheless remains uncertain: the carbonyl of the carboxamide is part of the lactam ring fused to the indole core, a case the definition does not expressly provide for. In case of doubt, caution calls for treating it as a narcotic.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Pulver et coll., pharmacologie et prévalence en Allemagne des SCRA à chaîne cyclobutylméthyle et norbornylméthyle, Drug Test Anal, 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"Giorgetti et coll., métabolisme de phase I humain du Cumyl-CBMEGACLONE et de deux analogues, Drug Test Anal, 2025","pmid":"39218806","doi":"10.1002/dta.3791","url":"https://pubmed.ncbi.nlm.nih.gov/39218806/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexes III et IV)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (listes de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-CB-MEGACLONE, CID 155884737","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/155884737"}],"meta":{"slug":"cumyl-cb-megaclone","url":"https://en.phytogrammes.com/wiki/cumyl-cb-megaclone","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}